Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,609.78
(
0.13%
)
US TECH 100
29,808.40
(
0.33%
)
Dow Jones
51,307.79
(
0.45%
)
Brent Oil
96.15
(
0.93%
)
Bitcoin
66,644.99
(
-0.06%
)
News Focus
News Focus
Post# of 828950
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ATLnsider

Send PM Follow Ignore
Followers 175
Posts 3513
Boards Moderated 1
Alias Born 11/03/2014

ATLnsider

Re: survivor1x post# 329794

Thursday, 11/12/2020 5:03:04 PM

Thursday, November 12, 2020 5:03:04 PM

Post# of 828950
I agree. I believe that with the vast amount of data that has been obtained in this DCVax-L Phase 3 trial, and because of its safety profile, NWBio will be able to get additional approvals for other operable solid tumor cancers in a much shorter period of time, using surrogate endpoints.

The FDA & the other RAs will probably require NWBio to conduct ongoing confirmatory trials to continue to track patients' Overall Survival (OS) over 3, 5, 7, years and further.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News